Advancing Multiple Sclerosis Treatment: Exploring Evolving Therapies and Patient-Centered Approaches

This activity was originally presented as a part of Neurology Pharmacy Day of Education 2025.

Program Description

Multiple sclerosis (MS) is a common immune-mediated demyelinating disease. While there have been advancements in understanding MS pathogenesis and developing disease-modifying therapies, many patients fail to respond due to lack of efficacy, adverse effects, poor tolerability, or poor adherence. Recently approved therapeutic agents, such as novel oral agents and monoclonal antibodies, are being developed to address these unmet medical needs for patients with relapsing and remitting MS. As frontline medication experts, pharmacists play a critical role in treatment selection, patient counseling, monitoring for adverse effects, and managing complex medication regimens. This session will review clinical guidelines, treatment goals such as preventing irreversible disability and reducing central nervous system inflammation, and best practices to provide informed, proactive support across the MS care continuum

Target audience: Specialty pharmacist

Type of activity: Application
Release date: June 20, 2025
Expiration date: June 20, 2026

Time to complete activity: 1.5 hours

Learner level: Intermediate, Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the clinical challenges and unmet needs in managing relapsing and progressive forms of multiple sclerosis (MS)
• Compare the efficacy and safety profiles of current and investigational therapies for the management of MS
• Apply patient-centered approaches to care, focusing on education and support to enhance quality of life and treatment outcomes for individuals with MS